甲氨蝶呤治疗异位妊娠的研究进展

Research Progress of Methotrexate in the Treatment of Ectopic Pregnancy

摘要: 异位妊娠(ectopic pregnancy, EP)是妇产科常见的急腹症，发病率约2%~3%，是妊娠早期孕妇死亡的主要原因。近年来，异位妊娠的发病患者逐渐趋于年轻化，且未婚、未育患者的比例有逐渐上升的趋势。保守治疗可以在治疗疾病的同时保护育龄期女性的生育功能，提高生育力，目前已经成为EP治疗的主要方向。甲氨蝶呤(Methotrexate, MTX)是异位妊娠保守治疗的常用药物。本文旨在对甲氨蝶呤在异位妊娠保守治疗中的进展进行综述。

Abstract: Ectopic pregnancy (EP) is a common acute abdomen in obstetrics and gynecology, with an incidence of about 2%~3%, which is the main cause of death in early pregnancy. In recent years, the incidence of ectopic pregnancy patients gradually tends to be younger, and the proportion of unmarried, nulliparous patients have a gradual upward trend. Conservative treatment can protect the reproductive function of women of childbearing age and improve fertility while treating diseases. It has become the main direction of EP treatment. Methotrexate (MTX) is a commonly used drug for conservative treatment of ectopic pregnancy. This article aims to review the progress of methotrexate in the conservative treatment of ectopic pregnancy.